Medivation (MDVN) Skyrockets As Prostate Cancer Drug Proven Effective
Tweet
Share
E-mail
Get Alerts MDVN Hot Sheet
Join SI Premium – FREE
Shares of Medivation, Inc. (Nasdaq: MDVN) have more than doubled early Thursday after the company and partner Astellas Pharma said the Independent Data Monitoring Committee (IDMC) informed them of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer.
MDV3100 successfully met the study's pre-specified interim efficacy stopping criteria, demonstrating a clinically meaningful and statistically significant (p < 0.0001) improvement in overall survival compared to placebo.
As a result of the positive results, the IDMC recommended the study be stopped early and men who received placebo be offered MDV3100.
The stock last traded at $37.25, up 127 percent from Wednesday's close.
MDV3100 successfully met the study's pre-specified interim efficacy stopping criteria, demonstrating a clinically meaningful and statistically significant (p < 0.0001) improvement in overall survival compared to placebo.
As a result of the positive results, the IDMC recommended the study be stopped early and men who received placebo be offered MDV3100.
The stock last traded at $37.25, up 127 percent from Wednesday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Falls 6%
- Tesla (TSLA) continues to slide, breaks under $150
- Super Micro Computer (SMCI) now down nearly 20%
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
